{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:11:59Z","timestamp":1791817919852,"version":"4.3.4"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>we present the case of the first documented occurrence of concurrent dermatomyositis and interstitial pneumonia associated with Trastuzumab Deruxtecan (T-DXd) therapy. We hypothesize that T-DXd likely induced an autoimmune response through tumor antigen release, resulting in multi-system involvement of skin, muscle, and pulmonary tissues. The shared pathogenesis of dermatomyositis and interstitial pneumonia involves aberrant activation of the type I interferon pathway, NF-\u03baB signaling, and TGF-\u03b2 cascade, collectively driving inflammatory and fibrotic processes. Notably, progression of breast cancer temporally coincided with the onset of dermatomyositis. Although anti-TIF1-\u03b3 antibodies were not detected, the possibility of paraneoplastic dermatomyositis cannot be definitively excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient\u2019s concerns and clinical findings<\/jats:title>\n                    <jats:p>a 43-year-old woman initially diagnosed with Luminal B-type invasive ductal carcinoma of the left breast and experienced tumor recurrence after modified radical mastectomy. Lymph node biopsy confirmed triple-negative breast cancer (cT2N3cM0, stage IIIC) with HER2 ultra-low expression (1+). During palliative second-line treatment with Trastuzumab Deruxtecan, patient developed typical dermatomyositis symptoms and proximal muscle weakness 7 days after the first cycle of administration. Following glucocorticoid treatment, dermatomyositis symptoms showed partial relief. However, with continued administration of T-DXd in compliance with original protocol (cycles 2-6), the manifestation of dermatomyositis significantly worsened. The condition remained poorly controlled despite administration of Prednisone combined with Hydroxychloroquine, and showed no significant improvement after adding methotrexate. Concurrent tumor evaluation revealed disease progression, too. Following the third treatment cycle, chest CT revealed interstitial pneumonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>reported here findings suggest that T-DXd may trigger multi-system involvement through immune-mediated mechanisms, resulting in drug-induced dermatomyositis and interstitial pneumonia. Our findings highlight the need for heightened vigilance regarding such immune-related adverse events during T-DXd therapy, where early recognition and intervention are critically important to avoid irreversible and possibly fatal complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1636581","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:29:25Z","timestamp":1762756165000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Possible association between dermatomyositis and Trastuzumab Deruxtecan therapy of triple-negative breast cancer patient"],"prefix":"10.3389","volume":"16","author":[{"given":"Huan","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksim","family":"Semenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1056\/NEJMicm2033425","article-title":"Dermatomyositis","volume":"384","author":"O\u2019Connell","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-023-00646-2","article-title":"Remarkable remission of symptomatic dermatomyositis after curative breast cancer surgery","volume":"13","author":"Fujino","year":"2024","journal-title":"Int Cancer Conf J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.5418","article-title":"Causes and clinical presentation of drug-induced dermatomyositis: A systematic review","volume":"160","author":"Caravan","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000517819","article-title":"Dermatomyositis following biosimilar trastuzumab in a breast cancer patient: A case report","volume":"14","author":"Moghimi","year":"2021","journal-title":"Case Rep Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00192","article-title":"Clinico-immunological profile of a 67-year-old woman affected by HER2-positive breast cancer and autoimmune dermatomyositis","volume":"10","author":"Pellegrino","year":"2020","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_209_19","article-title":"A case of trastuzumab-induced dermatomyositis","volume":"17","author":"Trontzas","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04204.x","article-title":"Hereditary complement (C9) deficiency associated with dermatomyositis","volume":"144","author":"Ichikawa","year":"2001","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.040717","article-title":"Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/08916930400022681","article-title":"Anti-mi-2 antibodies","volume":"38","author":"Ghirardello","year":"2005","journal-title":"Autoimmunity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-200406000-00018","article-title":"Uncertainties in the pathogenesis of adult dermatomyositis","volume":"17","author":"Greenberg","year":"2004","journal-title":"Curr Opin Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(02)00030-3","article-title":"Muscle biopsy findings in inflammatory myopathies. Rheumatic diseases clinics of North America; Rheumatic diseases clinics of North America","volume":"28","author":"Dalakas","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012236618892","article-title":"Mechanisms of cell-mediated myocytotoxicity in the peripheral blood of patients with inflammatory myopathies","volume":"21","author":"Bank","year":"2001","journal-title":"J Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118749","article-title":"Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis","volume":"97","author":"Goebels","year":"1996","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1711.2005.01390.x","article-title":"Development of murine plasmacytoid dendritic cell subsets","volume":"83","author":"Naik","year":"2005","journal-title":"Immunol Cell Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-011-0166-x","article-title":"Pathogenesis of dermatomyositis: role of cytokines and interferon","volume":"13","author":"Kao","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06166-3","article-title":"Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-\u03b3, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis\/polymyositis in a Japanese community hospital","volume":"41","author":"Suga","year":"2022","journal-title":"Clin Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410370709","article-title":"Immunopathogenesis of inflammatory myopathies","volume":"37","author":"Dalakas","year":"1995","journal-title":"Ann Neurol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S0889-857X(02)00029-7","article-title":"Genetic and environmental risk factors for idiopathic inflammatory myopathies","volume":"28","author":"Reed","year":"2002","journal-title":"Rheumatic Dis Clinics North America"},{"key":"B24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaad.2005.10.041","article-title":"A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies","volume":"54","author":"Gerami","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez301","article-title":"Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis\/dermatomyositis-interstitial lung disease","volume":"59","author":"Matsuda","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01045-w","article-title":"International guideline for idiopathic inflammatory myopathy-associated cancer screening: an international myositis assessment and clinical studies group (IMACS) initiative","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2002.04.1162","article-title":"Cancer-associated neuromusculoskeletal syndromes. Recognizing the rheumatic-neoplastic connection","volume":"111","author":"Marmur","year":"2002","journal-title":"Postgrad Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1990.01670290077012","article-title":"Prognostic factors and predictive signs of Malignancy in adult dermatomyositis. A study of 32 cases","volume":"126","author":"Basset-Seguin","year":"1990","journal-title":"Arch Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1084\/jem.20041367","article-title":"Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy","volume":"201","author":"Casciola-Rosen","year":"2005","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/ana.410230111","article-title":"Expression of immunoreactive major histocompatibility complex products in human skeletal muscles","volume":"23","author":"Karpati","year":"1988","journal-title":"Ann Neurol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0165-5728(02)00026-7","article-title":"Regulation of class I MHC expression in skeletal muscle: deleterious effect of aberrant expression on myogenesis","volume":"125","author":"Pavlath","year":"2002","journal-title":"J Neuroimmunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03630-w","article-title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","volume":"31","author":"Yin","year":"2025","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12916-023-03046-8","article-title":"A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis","volume":"21","author":"Liu","year":"2023","journal-title":"BMC Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1636581\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:29:26Z","timestamp":1762756166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1636581\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2025.1636581"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1636581","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"1636581"}}